Activities: The European Lung Cancer Congress (ELCC) webinar in May 2021 featured sessions on Early Stage Lung Cancer, Post EGFR, ALK, and Immuno-oncology. Activities included discussions on COVID-19's impact on lung cancer diagnosis, advancements in targeted therapies, and casebased analysis. Sponsored sessions by pharmaceutical companies highlighted cutting edge research, concluding with insights on treatment decisions and a comprehensive updates on lung cancer management.
Aim: The aim of the European Lung Cancer Congress (ELCC) webinar was to provide a comprehensive update on lung cancer, covering diverse topics such as early-stage diagnosis, targeted therapies, and immunotherapy. The sessions aimed to share expert insights, research findings, and case based discussions, fostering knowledge exchange among medical professionals for enhanced lung cancer management
Practical Application: Case-based analysis and sessions sponsored by pharmaceutical companies highlighted the practical implications of the latest research.
Patient Benefit: The diverse sessions aimed at improving treatment decisions, ultimately impacting patient outcomes and advancing the overall landscape of lung cancer care.
Knowledge Advancement: ELCC facilitated the dissemination of cutting edge information on early-stage lung cancer, targeted therapies, and immunotherapy.
Newsletter
